Pyxis Oncology shares are trading higher after the company announced that it will present its updated clinical data from its ongoing Phase 1 monotherapy study evaluating micvotabart pelidotin in patients with second-line and beyond recurrent/metastatic head and neck squamous cell carcinoma.